In the 2021 WHO Classification, the importance of molecular pathology in glioma diagnosis has been emphasized, particularly the status of isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion. The gene discussed is IDH2; the disease is central nervous system cancer.